Cargando…

Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPis) have been approved for the treatment of recurrent epithelial ovarian cancer (EOC), regardless of BRCA status or homologous recombination repair deficiency. However, the low response of platinum-resistant EOC, the emergence of resistance in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xi, Wang, Liqiong, Chen, Shu, Huang, Peng, Ma, Lan, Ding, Hui, Basappa, Basappa, Zhu, Tao, Lobie, Peter E., Pandey, Vijay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250505/ https://www.ncbi.nlm.nih.gov/pubmed/35791346 http://dx.doi.org/10.1038/s43856-022-00142-3

Ejemplares similares

Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma
por: Zhang, Xi, et al.
Publicado: (2022)

Investigation of NPB Analogs That Target Phosphorylation of BAD-Ser99 in Human Mammary Carcinoma Cells
por: Girimanchanaika, Swamy Savvemala, et al.
Publicado: (2021)

Discovery of Pyrimidine- and Coumarin-Linked Hybrid Molecules as Inducers of JNK Phosphorylation through ROS Generation in Breast Cancer Cells
por: Kim, Na Young, et al.
Publicado: (2023)

Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells
por: Vishwanath, Divakar, et al.
Publicado: (2023)

Novel Biphenyl Amines Inhibit Oestrogen Receptor (ER)-α in ER-Positive Mammary Carcinoma Cells
por: Basappa, Basappa, et al.
Publicado: (2021)

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase
por: Vishwanath, Divakar, et al.
Publicado: (2022)

De Novo Design of Imidazopyridine-Tethered Pyrazolines That Target Phosphorylation of STAT3 in Human Breast Cancer Cells
por: Ravish, Akshay, et al.
Publicado: (2023)

Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells
por: Basappa, Basappa, et al.
Publicado: (2023)

Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression
por: Cheng, Feifei, et al.
Publicado: (2022)

Development of Piperazine- and Oxazine-Linked Pyrimidines as p65 Subunit Binders of NF–κB in Human Breast Cancer Cells
por: Ravish, Akshay, et al.
Publicado: (2023)

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
por: Chong, Qing-Yun, et al.
Publicado: (2017)

Nano-Zirconium Dioxide Catalyzed Multicomponent Synthesis of Bioactive Pyranopyrazoles That Target Cyclin Dependent Kinase 1 in Human Breast Cancer Cells
por: Basappa, Basappa, et al.
Publicado: (2023)

Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma
por: Poh, Han Ming, et al.
Publicado: (2019)

Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK
por: Chen, Ru-Mei, et al.
Publicado: (2019)

Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells
por: Deveshegowda, Suresha N., et al.
Publicado: (2022)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives
por: Huang, Xinxin, et al.
Publicado: (2022)

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma
por: Zhang, Mengyi, et al.
Publicado: (2019)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Biodegradation of propiconazole by newly isolated Burkholderia sp. strain BBK_9
por: Satapute, Praveen, et al.
Publicado: (2016)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

New Heparanase-Inhibiting Triazolo-Thiadiazoles Attenuate Primary Tumor Growth and Metastasis
por: Barash, Uri, et al.
Publicado: (2021)

Epidemiology of Bovine Mastitis in Cows of Dharwad District
por: Kurjogi, Mahantesh M., et al.
Publicado: (2014)

1370. Role of Clindamycin Versus Linezolid for Serious Group A Streptococcal Infections
por: Heil, Emily, et al.
Publicado: (2021)

Comparison of landmark-guided and ultrasound-guided technique for superior laryngeal nerve block to aid fibreoptic intubation - An observational study
por: Magadum, Nandini Basappa, et al.
Publicado: (2023)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
por: Langelier, Marie-France, et al.
Publicado: (2014)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
por: Sebastian, Anusha, et al.
Publicado: (2016)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Bilateral fusion of permanent mandibular incisors with Talon's cusp: A rare case report
por: Prabhakar, Attiguppe Ramasetty, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8gbnad8kauqgftd4eloascq25q